Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114687 | 0.90 | ALDH1A1 (0.50) | DDB1CRBNALDH1A1ADAM17NPC1 | |
| SCHEMBL15967664 | 0.88 | DDB1 (0.46) | DDB1CRBNALDH1A1NR1H2NR1H3 | |
| SCHEMBL15967632 | 0.86 | DDB1 (0.52) | DDB1CRBNALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL18789282 | 0.81 | ATM (0.41) | CYP3A4CYP2C19KMT2A | |
| SCHEMBL3021875 | 0.80 | DDB1 (0.55) | DDB1CRBNALDH1A1NR1H2NR1H3 | |
| SCHEMBL25787780 | 0.80 | DDB1 (0.57) | DDB1CRBNALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL20002248 | 0.78 | DDB1 (0.44) | DDB1CRBNALDH1A1NR1H2NR1H3 | |
| SCHEMBL28529036 | 0.78 | DDB1 (0.44) | DDB1CRBNALDH1A1CYP3A4NPC1 | |
| SCHEMBL25360075 | 0.77 | TACR1 (0.47) | NPC1RAB9AKMT2A | |
| SCHEMBL19208963 | 0.76 | DDB1 (0.53) | DDB1CRBNALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249180-B2 | C-3 alkyl and alkenyl modified betulinic acid derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249180-B2 | C-3 alkyl and alkenyl modified betulinic acid derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249180-B2 | C-3 alkyl and alkenyl modified betulinic acid derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2958930-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV | Bristol-Myers Squibb Company (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130810-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014130810-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | BET1, TMPO, PGGT1B | DDB1 2136/4885CRBN 3784/4885ALDH1A1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.